share_log

Nestle Bets €40M On Enterome's Preclinical Food Allergy, IBD Hopeful

Nestle Bets €40M On Enterome's Preclinical Food Allergy, IBD Hopeful

雀巢将4000万欧元押注于Enterome的临床前食物过敏，IBD有望
Benzinga Real-time News ·  2022/07/18 15:00
  • France-based Enterome signed a strategic R&D collaboration and license agreement with Nestlé SA's (OTC:NSRGF) Health Science, targeting food allergies and inflammatory bowel disease (IBD).
  • Enterome's internal pipeline is more focused on cancer, with phase 1/2 trials of two drug candidates underway in indications including recurrent glioblastoma and B-cell malignancies. 
  • The biotech is also working on a Crohn's disease prospect that is in phase 2 development in partnership with Takeda Pharmaceutical Co Ltd (NYSE:TAK).
  • Now, Enterome has found a partner for its lead EndoMimics compound designed to create orally available drugs based on proteins secreted by gut bacteria.
  • Nestlé will pay €40 million in cash and equity, clinical, and sales milestone payments for each licensed therapeutic candidate, plus royalties on net sales.
  • Nestlé will co-develop EB1010 designed to treat inflammatory bowel disease by inducing high local secretion of the anti-inflammatory cytokine IL-10. 
  • Enterome will be responsible for leading drug discovery activities and bear related costs up to the investigational new drug (IND) application.
  • EB1010 is due to enter clinical trials in 2023.
  • Price Action: NSRGF shares are down 0.20% at $117.43 during the market session on the last check Monday.
  • 总部位于法国肠胃与中国签署了战略研发合作和许可协议雀巢公司(场外交易代码：NSRGF)健康科学，针对食物过敏和炎症性肠病(IBD)。
  • Enterome的内部流水线更专注于癌症，两种候选药物的1/2期试验正在进行中，适应症包括复发性胶质母细胞瘤和B细胞恶性肿瘤。
  • 这家生物技术公司还在研究克罗恩病的前景，该疾病正与以下公司合作处于第二阶段开发武田药品工业株式会社(纽约证券交易所股票代码：Tak)。
  • 现在，Enterome已经为其Lead EndoMimics化合物找到了合作伙伴，该化合物旨在基于肠道细菌分泌的蛋白质创造口服药物。
  • 雀巢将为每个获得许可的治疗候选药物支付4000万欧元的现金和股权、临床和销售里程碑付款，以及净销售额的特许权使用费。
  • 雀巢将共同开发EB1010，旨在通过诱导局部高分泌抗炎细胞因子IL-10来治疗炎症性肠病。
  • Enterome将负责领导药物发现活动，并承担研究新药(IND)申请的相关费用。
  • EB1010将于2023年进入临床试验。
  • 价格行动：周一收盘时，nsrgf股价下跌0.20%，至117.43美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发